

# NCI SBIR AND YOUR STATE:

## NEW JERSEY



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$24.8 million** in funding across **25 Phase II SBIR/STTR grants** to small businesses in New Jersey. The following economic impact estimates quantify the program's contributions to the state's economy:



**\$16.5M**

**IN TOTAL DIRECT SALES**



**\$344.7M**

**IN TOTAL ECONOMIC IMPACT**



**1.5K**

**JOBS CREATED**



**\$17.3M**

**IN STATE & LOCAL TAXES COLLECTED**



**8**

**COMPANIES WITH SALES**

*\*These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in New Jersey: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$76.3M in funding across all grants to oncology-focused small businesses in the state.*

### Success stories include:

#### **VIOCARE, INC.**

Viocare used SBIR funding to commercialize three separate nutritional assessment technologies, two of which are used by government agencies and leading life science research organizations to conduct dietary studies and clinical trials.

#### **IMMUNOMEDICS, INC.**

SBIR awardee Immunomedics developed Trodelvy®, an antibody-drug conjugate that has received FDA approvals for treatment of several types of breast cancer. The company was part of a \$21 billion acquisition agreement with Gilead Sciences in 2020.

**The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to [ncisbir@mail.nih.gov](mailto:ncisbir@mail.nih.gov).**